GSK3β Inhibitor Peptide Protects Mice from LPS-induced Endotoxin Shock

키워드

참고문헌 (40)

1. Cohen P, "The renaissance of GSK3", Nat Rev Mol Cell Biol, 2, pp.769~776 (2001)
2. Frame S, "GSK3 takes centre stage more than 20 years after its discovery", Biochem J, 359, pp.1~16 (2001)
3. Woodgett JR, "Judging a protein by more than its name: GSK-3", Sci STKE (2001)
4. Embi N, "Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMPdependent protein kinase and phosphorylase kinase", Eur J Biochem, 107, pp.519~527 (1980)
5. Beals CR, "Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3", Science, 275, pp.1930~1934 (1997)
6. El Jamali A, "Reoxygenation after severe hypoxia induces cardiomyocyte hypertrophy in vitro: activation of CREB downstream of GSK3 beta", FASEB J, 18, pp.1096~1098 (2004)
7. Wei W, "The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase", Cancer Cell, 8, pp.25~33 (2005)
8. Gregory MA, "Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization", J Biol Chem, 278, pp.51606~51612 (2003)
9. Liang J, "Multiple roles of the PI3K", PKB (Akt) pathway in cell cycle progr, 2003, pp.2, 339~345
10. Gum RJ, "Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob", ob mice, 2003, pp.52, 21~28
11. Ring DB, "Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo", Diabetes, 52, pp.588~595 (2003)
12. Martinez A, "GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease?", J Alzheimers Dis, 15, pp.181~191 (2008)
13. Beaulieu JM, "Akt", GSK3 signaling in the action of psychotropic drugs, 2009, pp.49, 327~347
14. Inoki K, "TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth", Cell, 126, pp.955~968 (2006)
15. Martin M, "Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3", Nat Immunol, 6, pp.777~784 (2005)
16. Hu X, "IFN-gamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB", AP-1 proteins, 2006, pp.24, 563~574
17. Rehani K, "Toll-like receptor-mediated production of IL-1Ra is negatively regulated by GSK3 via the MAPK ERK1", 2, 2009, pp.182, 547~553
18. Beurel E, "Glycogen synthase kinase-3 promotes the synergistic action of interferon-gamma on lipopolysaccharide- induced IL-6 production in RAW264.7 cells", Cell Signal, 21, pp.978~985 (2009)
19. Cohen P, "GSK3 inhibitors: development and therapeutic potential", Nat Rev Drug Discov, 3, pp.479~487 (2004)
20. Wada A, "GSK-3 inhibitors and insulin receptor signaling in health, disease, and therapeutics", Front Biosci, 14, pp.1558~1570 (2009)
21. Phukan S, "GSK3beta: role in therapeutic landscape and development of modulators", Br J Phamacol, 160, pp.1~19 (2010)
22. Plotkin B, "Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3", J Pharmacol Exp Ther, 305, pp.974~980 (2003)
23. Fischer PM, "CDK versus GSK-3 inhibition: a purple haze no longer?", Chem Biol, 10, pp.1144~1146 (2003)
24. Phiel CJ, "Molecular targets of lithium action", Annu Rev Pharmacol Toxicol, 41, pp.789~813 (2001)
25. Sawa M, "Strategies for the design of selective protein kinase inhibitors", Mini Rev Med Chem, 8, pp.1291~1297 (2008)
26. Dajani R, "Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition", Cell, 105, pp.721~732 (2001)
27. Frame S, "A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation", Mol Cell, 7, pp.1321~1327 (2001)
28. ter Haar E, "Structure of GSK3beta reveals a primed phosphorylation mechanism", Nat Struct Biol, 8, pp.593~596 (2001)
29. Choi JM, "Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation", Nat Med, 12, pp.574~579 (2006)
30. Kim H, "Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice", J Clin Invest, 119, pp.813~825 (2009)
31. Beurel E, "Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3)", Trends Immunol, 31, pp.24~31 (2010)
32. Jope RS, "Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics", Neurochem Res, 32, pp.577~595 (2007)
33. Rayasam GV, "Glycogen synthase kinase 3: more than a namesake", Br J Pharmacol, 156, pp.885~898 (2009)
34. Bax B, "The structure of phosphorylated GSK-3beta complexed with a peptide, FRATtide, that inhibits beta-catenin phosphorylation", Structure, 9, pp.1143~1152 (2001)
35. Rommel C, "Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K", Akt, Akt, pp.GSK3 pathways, Nat Cell Biol[DOI]
36. Mottet D, "Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase", Akt, J Biol Chem, pp.2003, 278[DOI]
37. Cross DA, "Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B", Nature, 378, pp.785~789 (1995)
38. Doble BW, "GSK-3: tricks of the trade for a multi-tasking kinase", J Cell Sci, 116, pp.1175~1186 (2003)
39. Plotkin B, "Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3", J Pharmacol Exp Ther, 305, pp.974~980 (2003)
40. Sato AK, "Therapeutic peptides: technological advances driving peptides into development", Curr Opin Biotechnol, 17, pp.638~642 (2006)

관련 논문AI추천